glp-1 drugs and alcohol A cheap, already available pill is being billed as the “Ozempic of alcohol” for its ability to reduce appetites for booze, the way curb food cravings GLP-1 drugs and alcohol reduction
Description
Participants with significant side effects at the lower doses were held at 0.5mg at week 9 dosing

Sawami K, Tanaka A, Node K (2022) Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists

Originally FDA-approved for type 2 diabetes, several now carry indications for weight management and cardiovascular risk reduction

Its potential ability to inhibit carbohydrate absorption makes it a valuable addition to the blend

Front Endocrinol (Lausanne) 2024;15 doi: 10.3389/fendo.2024.1330936

The ATLAS Community Health Initiative is supported by UCLA Health, the David Geffen School of Medicine and a grant from the UCLA Clinical and Translational Science Institute (UL1TR001881)
